Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3
Open accessAbstract
// Peipei Yang 1, * , Weicai Chen 1, * , Xuhui Li 2 , Grant Eilers 3 , Quan He 1 , Lili Liu 1 , Yeqing Wu 1 , Yuehong Wu 1 , Wei Yu 1 , Jonathan A. Fletcher 3 , Wen-Bin Ou 1, 2, 3 1 Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, China 2 Zhejiang Provincial Key Laboratory of Applied Enzymology, Yangtze Delta Region Institute of Tsinghua University, Jiaxing, Zhejiang, China 3 Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA * These authors contributed equally to this work Correspondence to: Wen-Bin Ou, email: ouwenbin@tsinghua.org.cn Keywords: cyclin D1, MDM2, p53, upregulation, Nutlin-3 Received: January 10, 2016 Accepted: March 31, 2016 Published: April 26, 2016 ABSTRACT The MDM2-p53 pathway has a prominent oncogenic function in the pathogenesis of various cancers. Nutlin-3, a small-molecule antagonist of MDM2-p53 interaction, inhibits proliferation in cancer cells with wild-type p53. Herein, we evaluate the expression of MDM2, both the full length and a splicing variant MDM2-A, and the sensitivity of Nutlin-3 in different cancer cell lines. Included are seven cell lines with wild-type p53 (four mesothelioma, one breast cancer, one chondrosarcoma, and one leiomyosarcoma), two liposarcoma cell lines harboring MDM2 amplification and wild-type p53, and one mesothelioma cell line harboring a p53 point mutation. Nutlin-3 treatment increased expression of cyclin D1, MDM2, and p53 in cell lines with wild-type p53. Additive effects were observed in cells containing wild-type p53 through coordinated attack on MDM2-p53 binding and cyclin D1 by lentivirual shRNA knockdown or small molecule inhibition, as demonstrated by immunoblots and cell viability analyses. Further results demonstrate that MDM2 binds to cyclin D1, and that an increase in cyclin D1 expression after Nutlin-3 treatment is correlated with expression and ubiquitin E3-ligase activity of MDM2. MDM2 and p53 knockdown experiments demonstrated inhibition of cyclin D1 by MDM2 but not p53. These results indicate that combination inhibition of cyclin D1 and MDM2-p53 binding warrants clinical evaluation as a novel therapeutic strategy in cancer cells harboring wild-type p53.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Cyclin D1 physically associates with MDM2.
“This notion is further strengthened by a recent report on a physical association between Cyclin D1 and MDM238.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · see citing works
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · see citing works
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967 · see citing works
KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.
Rubin, B. P., Singer, S., Tsao, C., Duensing, A. U., Lux, M. L., Ruiz, R., Hibbard, M. K., Chen, C. J., Xiao, S., Tuveson, D. A., et al. (2001) · PubMed · Cited by 959 · see citing works
Self-citationp53 ubiquitination: Mdm2 and beyond
Brooks, C. L., & Gu, W. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.020 · Cited by 924 · see citing works
Inhibiting the p53–MDM2 interaction: an important target for cancer therapy
Chène, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc991 · Cited by 765 · see citing works
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708 · see citing works
Molecular Mechanism of the Interaction between MDM2 and p53
Schön, O., Friedler, A., Bycroft, M., Freund, S. M. V., & Fersht, A. R. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00852-5 · Cited by 349 · see citing works
MDM2 Promotes Proteasome-Dependent Ubiquitin-Independent Degradation of Retinoblastoma Protein
Sdek, P., Ying, H., Chang, D. L. F., Qiu, W., Zheng, H., Touitou, R., Allday, M. J., & Jim Xiao, Z.-X. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.10.017 · Cited by 288 · see citing works
Tovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2807 · Cited by 283 · see citing works
Sigalas, I., Calvert, A. H., Anderson, J. J., Neal, D. E., & Lunec, J. (1996) · Nature Medicine · doi:10.1038/nm0896-912 · Cited by 268 · see citing works
The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma
Slack, A., Chen, Z., Tonelli, R., Pulè, M. A., Hunt, L., Pession, A., & Shohet, J. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405495102 · Cited by 235 · see citing works
MDM2–p53 Pathway in Hepatocellular Carcinoma
Meng, X., Franklin, D. A., Dong, J., & Zhang, Y. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1446 · Cited by 216 · see citing works
Canon, J., Osgood, T., Olson, S. H., Saiki, A. Y., Robertson, R., Yu, D., Eksterowicz, J., Ye, Q., Jin, L., Chen, A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0710 · Cited by 152 · see citing works
Pilotti, S., Torre, G. D., Lavarino, C. E., Palma, S. D., Sozzi, G., Minoletti, F., Rao, S., PASQUINI, G., Azzarelli, A., Rilke, F. O., et al. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199701)181:1 · Cited by 149 · see citing works
Demetri, G. D., Zenzie, B. W., Rheinwald, J. G., & Griffin, J. D. (1989) · Blood · doi:10.1182/blood.v74.3.940.940 · Cited by 145 · see citing works
An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2
Evans, S. C., Viswanathan, M., Grier, J. D., Narayana, M., El‐Naggar, A. K., & Lozano, G. (2001) · Oncogene · doi:10.1038/sj.onc.1204533 · Cited by 138 · see citing works
Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
Lukáš, J., Gao, D. Q., Keshmeshian, M., Wen, W., Tsao-Wei, D. D., Rosenberg, S. A., & Press, M. F. (2001) · PubMed · Cited by 133 · see citing works
Maerken, T. V., Ferdinande, L., Taildeman, J., Lambertz, I., Yigit, N., Vercruysse, L., Rihani, A., Michaelis, M., Cinatl, J. J., Cuvelier, C. A., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp355 · Cited by 120 · see citing works
Ito, M., Barys, L., O'Reilly, T., Young, S., Gorbatcheva, B., Monahan, J., Zumstein-Mecker, S., Choong, P. F., Dickinson, I., Crowe, P., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2050 · Cited by 115 · see citing works
AXL regulates mesothelioma proliferation and invasiveness
Ou, W.-B., Corson, J. M., Flynn, D. L., Lu, W.-P., Wise, S., Bueno, R., Sugarbaker, D. J., & Fletcher, J. A. (2010) · Oncogene · doi:10.1038/onc.2010.555 · Cited by 96 · see citing works
Self-citationAn Alternative Splice Form of Mdm2 Induces p53-independent Cell Growth and Tumorigenesis
Steinman, H. A., Burstein, E., Lengner, C., Gosselin, J., Pihan, G., Duckett, C. S., & Jones, S. N. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m305966200 · Cited by 96 · see citing works
Snyder, E. L., Sandstrom, D. J., Law, K., Fiore, C., Sicińska, E., Brito, J. M., Bailey, D., Fletcher, J. A., Loda, M. F., Rodig, S. J., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2564 · Cited by 89 · see citing works
Self-citationTumor promotion by Mdm2 splice variants unable to bind p53.
Fridman, J. S., Hernando, E., Hemann, M. T., de Stanchina, E., Cordon‐Cardo, C., & Lowe, S. W. (2003) · PubMed · Cited by 82 · see citing works
Protein kinase C-θ regulates KIT expression and proliferation in gastrointestinal stromal tumors
Ou, W.-B., Zhu, M.-J., Demetri, G. D., et al. (2008) · Oncogene · doi:10.1038/onc.2008.177 · Cited by 77 · see citing works
Self-citationTargeted Inhibition of Multiple Receptor Tyrosine Kinases in Mesothelioma
Ou, W., Hubert, C. G., Fletcher, J. A., et al. (2011) · Neoplasia · doi:10.1593/neo.101156 · Cited by 72 · see citing works
Self-citationWęglarz, L., Molin, I., Orchel, A., Parfiniewicz, B., & Dzierżewicz, Z. (2006) · Acta Biochimica Polonica · doi:10.18388/abp.2006_3348 · Cited by 60 · see citing works
Identifying the determinants of response to MDM2 inhibition
Saiki, A. Y., Caenepeel, S. R., Cosgrove, E. J., Su, C., Boedigheimer, M. J., & Oliner, J. D. (2015) · Oncotarget · doi:10.18632/oncotarget.3116 · Cited by 39 · see citing works
Ou, W., Zhu, J., Eilers, G., Li, X., Kuang, Y., Liu, L., Mariño‐Enríquez, A., Yan, Z., Li, H., Meng, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3230 · Cited by 38 · see citing works
Self-citationHsiang, C., & Straus, D. S. (2002) · Oncogene · doi:10.1038/sj.onc.1205293 · Cited by 27 · see citing works
MDMX exerts its oncogenic activity via suppression of retinoblastoma protein
Zhang, H., Hu, L., Qiu, W., Deng, T., Zhang, Y., Bergholz, J. S., & Xiao, Z.-X. (2015) · Oncogene · doi:10.1038/onc.2015.11 · Cited by 26 · see citing works
Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells
Sui, X., Shin, S., Zhang, R., Firozi, P. F., Yang, L., Abbruzzese, J. L., & Reddy, S. A. G. (2009) · Oncogene · doi:10.1038/onc.2008.423 · Cited by 25 · see citing works
Thomázy, V. A., Luthra, R., Uthman, M. O., et al. (2002) · Journal of Molecular Diagnostics · doi:10.1016/s1525-1578(10)60704-0 · Cited by 25 · see citing works
Inhibition of estrogen-dependent breast cell responses with phenylacetate
Sawatsri, S., Samid, D., Malkapuram, S., & Sidell, N. (2001) · International Journal of Cancer · doi:10.1002/ijc.1399 · Cited by 23 · see citing works
Sánchez‐Aguilera, A., García, J. F., Sánchez‐Beato, M., & Piris, M. A. (2005) · Oncogene · doi:10.1038/sj.onc.1209282 · Cited by 21 · see citing works
Bozzi, F., Conca, E., Laurini, E., Posocco, P., Sardo, A. L., Jocollé, G., Sanfilippo, R. G., Gronchi, A., Perrone, F., Tamborini, E., et al. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.107 · Cited by 20 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Sriraman, A., Dickmanns, A., Najafova, Z., Johnsen, S. A., & Dobbelstein, M. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0968-0 · Cited by 40 · see citing works
- Authors
- Yang, P., Chen, W., Li, X., Eilers, G., He, Q., Liu, L., Wu, Y., Wu, Y., Yu, W., Fletcher, J. A., & Ou, W.-B.
- Affiliations
- Zhejiang Sci-Tech University (CN)
- Tsinghua University (CN)
- Brigham and Women's Hospital (US)
- Corresponding author
- Yang, Peipei
- Chen, Weicai
- ORCID
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-04-26
- Volume
- 7
- Issue
- 22
- Pages
- 32652-32663
- ISSN
- 1949-2553 (ISSN-L)
- PMC
- PMC5078041
- OpenAlex
- W2342884001
- Cited by
- 21
- References
- 36
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 3 · 2021: 2 · 2020: 3 · 2019: 2 · 2018: 5 · 2017: 2 · 2016: 1
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Oncotarget (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- Brigham and Women's Hospital
- Zhejiang Sci-Tech University (14042107-Y, 2011AA100603)
- National High-tech Research and Development Program
- National Cancer Institute (P50CA127003)
- Natural Science Foundation of Zhejiang Province (2011AA100603)
- Science and Technology Program of Zhejiang Province
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- cyclin D1, MDM2, Nutlin-3, p53-MDM2 interaction, p53, MDM2 amplification, TP53 mutation, mesothelioma, liposarcoma, breast cancer, chondrosarcoma, leiomyosarcoma
- MeSH terms
- Humans, Imidazoles, Neoplasms, Piperazines, Down-Regulation, Tumor Suppressor Protein p53, Cyclin D1, Cell Line, Tumor, Proto-Oncogene Proteins c-mdm2, Gene Knockdown Techniques, HEK293 Cells, MCF-7 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
